Esperion Therapeutics Hits Day Low of $2.83 Amid Price Pressure

Esperion Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 11.01%. The stock reached an intraday low of USD 2.83, reflecting ongoing challenges within the company. Over the past week, Esperion has seen a decrease of 11.82%, and its performance over the last month has been even more pronounced, with a decline of 17.09%. Year-to-date, the stock is down 21.35%, contrasting sharply with its impressive one-year performance of 84.18%. However, this recent downturn highlights a troubling trend, as the stock has plummeted 54.1% over the past three years and 89.41% over the last five years. Financial metrics indicate a weak long-term fundamental strength, with a negative book value and a poor EBIT to interest ratio of -2.53. The company has also reported a significant increase in raw material costs, which rose by 21.02% year-over-year. With cash and equivalents at a low of USD 178.51 million and interest expenses peaking at USD 22.05 million, the financial outlook appears challenging for Esperion Therapeutics.